BioNexus Gene Lab Corp Common stock (BGLC) support and resistance · rev $9.5M
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
This page maps BioNexus Gene Lab Corp Common stock (BGLC) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
BGLC currently screens at market cap $6.1M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new BGLC 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the BGLC quote page for the session range and the stock page for the full model.
Not investment advice.